← All trials
NCT04488081
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2020
- Primary completion
- Jul 24, 2022
- Completion date
- Nov 1, 2022
- First posted
- Jul 27, 2020
- Last posted
- Sep 29, 2020
- Enrollment
- 1500
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- QuantumLeap Healthcare CollaborativeLead sponsor
- Wake Forest UniversityCollaborator
- University of California, San DiegoCollaborator
- Yale UniversityCollaborator
- Emory UniversityCollaborator
- University of California, San FranciscoCollaborator
- University of California, San FranciscoOverall official - principal investigator
- Yeshiva UniversityCollaborator
- University of PennsylvaniaCollaborator
- University of Alabama, BirminghamCollaborator
- University of Colorado, DenverCollaborator
- Columbia UniversityCollaborator
- University of Southern CaliforniaCollaborator
- Sanford HealthCollaborator
- University of MinnesotaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.